Group 1: Company Performance and Financials - IQVIA reported fourth-quarter revenue of $4.36 billion, exceeding the consensus estimate of $4.08 billion [3] - The company achieved near double-digit revenue and EPS growth in 2025, with strong performance across all segments [3] - CEO Ari Bousbib highlighted that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth [3] Group 2: Analyst Ratings and Price Target - Morgan Stanley lowered its price target on IQVIA Holdings Inc. to $240 from $265 but maintained an Overweight rating [1][5] - The adjustment in price target followed the company's quarterly results [1] Group 3: Strategic Collaborations - IQVIA and the Duke Clinical Research Institute announced a collaboration to advance clinical research in obesity and related cardiometabolic trials [2] - The partnership aims to set a new standard for collaboration between life science service companies and academic research organizations, focusing on improving trial efficiency [2]

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $28 billion by market cap, the company offers analytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. Shares of this contract research giant have underperformed the broader market over the past year. IQV has declined 11.4% over thi ...

Have you evaluated the performance of IQVIA Holdings' (IQV) international operations for the quarter ending December 2025? Given the extensive global presence of this clinical testing company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 IQVIA HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 27-1341991 (State or other jurisdiction ...

Core Viewpoint - Investors in IQVIA Holdings Inc. should closely monitor the stock due to significant movements in the options market, particularly the high implied volatility of the Feb 20, 2026 $105.00 Call option [1] Company Analysis - IQVIA is currently rated as Zacks Rank 4 (Sell) within the Medical - Instruments Industry, which ranks in the top 34% of the Zacks Industry Rank [3] - Over the past 60 days, no analysts have increased their earnings estimates for the current quarter, while four analysts have revised their estimates downward, leading to a decrease in the Zacks Consensus Estimate from $2.94 per share to $2.87 per share [3] Options Market Insights - The high implied volatility surrounding IQVIA shares suggests that options traders are anticipating a significant price movement, which could indicate an upcoming event that may lead to a substantial rally or sell-off [2][4] - Options traders often seek to capitalize on high implied volatility by selling premium, aiming for the underlying stock to not move as much as initially expected by expiration [4]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - Australia is recognized for its mature R&D ecosystem, established regulatory pathways, and cost-effective clinical trial environment for Cell and Gene Therapy (CAGT) products [4][5][6] - The country has over 160 ongoing industry CAGT trials, with a focus on oncology, autoimmune diseases, and cardiovascular conditions [9][12] - IQVIA is highlighted as a leading Contract Research Organization (CRO) in Australia, providing comprehensive support for CAGT products from pre-clinical to post-marketing stages [24][29] Summary by Sections Why Australia for CAGT Trials? - Australia offers a cost-effective and mature clinical research infrastructure, with high-quality data accepted by global regulators [5][6] - The regulatory framework allows for rapid trial initiation and approvals, with minimal documentation required [7][11] - The favorable AUD exchange rate and R&D tax incentives contribute to lower trial costs compared to the U.S. [7] Mature R&D Ecosystem - Australia hosts over 160 ongoing CAGT trials, with a robust clinical research infrastructure and experienced investigators [9][11] - The country has established treatment centers for complex therapies, including CAR-T, and offers end-to-end support from CDMO partners [10][11] Established and Favorable Regulatory Pathway - The Clinical Trial Notification (CTN) process allows for a fast regulatory start-up, typically taking around 7 to 10 days [14][17] - The Therapeutic Goods Administration (TGA) does not evaluate clinical trial data under the CTN scheme, focusing instead on product safety [18] IQVIA, the Leading CRO in Australia - IQVIA provides a local presence with global capabilities, supporting CAGT trials through a network of sites and a dedicated study management team [26][28] - The organization has participated in the clinical development of 17 approved CAGT products, showcasing its expertise in the field [33] Global Reach and Local Impact - IQVIA's capabilities allow for seamless integration of new countries into multi-regional development plans for CAGT products [26][30] - The company offers a comprehensive strategy for commercialization, policy shaping, and stakeholder engagement [29]

White Paper Optimizing Early-Phase Clinical Trials for Rapid, Evidence- Based Decision Making Leveraging the rapidly evolving design and delivery strategies to safely accelerate molecule advancement ELIZABETH ALLEN, PhD, Vice-President, Early Phase Development Centre of Excellence, Scientific Strategy RAYMOND COOK, MD, Vice President, Medical Strategy for Early Phase Development JOANNE EMANUEL, Senior Director, Clinical Project Management, Early Phase JOCHEN ZESCHKY, Senior Therapeutic Strategy Lead Directo ...

Key Takeaways IQVIA beat Q4 earnings and revenue estimates, delivering 9.6% EPS growth and 10.3% Y/Y revenue rise.IQV posted segment gains: R&D and Technology & Analytics grew about 10%, while Contract Sales surged 18.6%.IQVIA guided 2026 revenues at $17.15-$17.35B and reported $2B cash with $561M in Q4 free cash flow.IQVIA Holdings Analytics Inc. (IQV) has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $3.42 per share, ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - Senior VP of Investor Relations and TreasuryMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Resear ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - VP of Investor RelationsMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Research AnalystJustin Bow ...